Pembrolizumab-induced diabetes

Pembrolizumab is a check-point inhibitor that is used for the treatment of advanced malignancies. Endocrinopathies, including hypophysitis, thyroiditis, diabetes mellitus, etc., are increasingly recognised as complications of Pembrolizumab. Here, we report a case of an 83-year-old female who presented with osmotic symptoms, elevated blood glucose levels, and elevated blood ketones following treatment with Pembrolizumab for metastatic melanoma. With the increasing use of these agents, it is more important than ever that physicians understand the complications and subsequent management of these patients.